The HCPLive Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.
October 3rd 2024
A study reveals that individuals with schizophrenia spectrum disorders experience high rates of comorbid mental health conditions and receive minimally adequate treatment.
September 26th 2024
September 20th 2024
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
SNAP Program Leads to Less Food Insecurity, Mental Illness Rates
State adoption of both SNAP eligibility policies, where the state eliminates the asset test and increases the income limit resulted in decreases in the rates of past-year major depressive episodes, mental illness, serious mental illness, and suicidal ideation.
Electroconvulsive Therapy Bests Ketamine in Treating Major Depressive Episodes
Electroconvulsive therapy was superior to ketamine in a sensitivity analysis of methodologically stronger trials and also was better in study-defined response and remission for patients with major depressive episodes.
fNIRS Investigation of Brain Activity, Cognitive Function and Sleep Quality in Major Depression
April 6th 2023A new study has found individuals with depression and insomnia show significantly less activity in the prefrontal cortex during verbal fluency tests, suggesting that sleep quality is an important indicator in fNIRS screening.
Investigators Identify Risk Factors for Drug-Induced Parkinsonism for Schizophrenia Patients
Various psychiatric symptoms, including more severe negative symptoms, lower cognition status, and lower excited symptoms were significantly linked to drug-induced parkinsonism induction.
FDA Will Not Hold Advisory Meeting for MDD, PPD Drug Application
Zuranolone is being evaluated as a 14 day, rapid-acting, once-daily, oral treatment for adult patients with MDD and PPD. The drug is an oral neuroactive steroid GABA-A receptor positive allosteric modulator.
New Research Seeks Explanation of Antidepressant Placebo Effect
The results from a Bayesian reinforcement learning model showed the antidepressant placebo trial-wise expectancies were updated by composite learning signals multiplexing sensory evidence and trial-wise mood.